Therapies – discovery and development (2)
C166 – C197
- C166: KU-0059436 plus radiation as first line therapy for glioblastoma multiforme: rationale and phase I clinical trial protocol
- C167: In vitro and in vivo evaluation of a novel 18F-labeled isatin as an apoptosis PET imaging tracer
- C168: Imaging the biological activity of AKT-kinase-platinum drug combinations in vivo
- C169: Treatment of disseminated melanoma with 211At-methylene blue
- C170: Setting up a multi-centre cancer biobank: key learning points
- C171: Bioavailability of four different sublingual formulations of fentanyl in healthy male volunteers: Phase I, randomised, open-label, crossover study
- C172: Vandetanib shows potent efficacy against an EGFR dependent model of human lung cancer
- C173: A novel small molecule inhibits cancer cell proliferation in vitro and in vivo via activation of the protein kinase AMPK
- C174: Isoindolinone inhibitors of the MDM2-p53 protein-protein interaction: structure-activity studies
- C175: Therapeutic targeting of c-FLIP with antisense phosphorothioate oligonucleotides
- C176: Non-invasive imaging of Mitogenic Extracellular Kinase inhibition by PD0325901
- C177: Characterisation of the Janus Kinase inhibitory activity of novel kinase inhibitor AT9283
- C178: Molecular mechanisms of T cell recruitment into renal cell carcinoma
- C179: Ascorbate (Vitamin C) accelerates hydrogen-peroxide induced cell death in SK23 melanoma cells: vitamin C modulates the immune system?
- C180: Development of a novel, anti-angiogenic peptide derived from the C-terminal of MMP-inhibitor, TIMP-3
- C181: Use of nanomagnets to enhance monocyte delivery of gene therapy to tumours
- C182: Adenovirus 11: a potential oncolytic virus for pancreatic cancer therapy?
- C183: Efficient lentiviral transduction of primary mouse T cells
- C184: Increasing melanoma cell death using an inhibitor of protein disulphide isomerases to abrogate stress-survival responses
- C185: IgE antibody immunotherapy of solid tumours: A novel model targeting folate receptor with MOv18 IgE
- C186: Patterns of bone metastases and bisphosphonate use in renal cancer patients in Leeds, UK
- C187: Immunotherapy of primary leukaemia by WT1-TCR engineered patient’s autologous T cells
- C188: In vitro activity of the multitargeted receptor tyrosine kinase inhibitor sunitinib against multiple myeloma cell lines is not predictive of in vivo xenograft response
- C189: Stimulation of VEGF-mediated angiogenesis and tumor growth by low concentrations of anti-angiogenic integrin inhibitors
- C190: Dietary flavonoids inhibit the anti-cancer effects of the proteasome inhibitor Bortezomib
- C191: Inhibiting BCL-6
- C192: CRT0066101, a small molecule inhibitor of protein kinase D, demonstrates in vitro and in vivo anticancer efficacy
- C193: Identification and characterisation of small molecule inhibitors of the atypical protein kinase C family (aPKC)
- C194: The αvβ6 integrin - a novel target for antibody conjugated magnetic fluid hyperthermia in squamous cell carcinoma
- C195: An in vitro study of the pro‑apoptotic properties of green tea polyphenols in neoplastic cell lines
- C196: Second-line treatment of ovarian carcinoma with pegylated liposomal doxorubicin (Caelyx®)
- C197: Changes in Ca-125 relative to response following treatment with Pegylated Liposomal Doxorubicin (Caelyx®) in ovarian carcinoma
